IC-OS Working Group Webinar - Case Studies in Anthracycline Cardiotoxicity

Charles Porter MD established the Cardio-oncology program for the University of Kansas Cancer at the University of Kansas Medical Center in 2007. He was designated as the inaugural American Vice-President of IC-OS in 2009. He has overseen the growth of the KUMC cardio-oncology program and continues to expand its collaboration with a broad array of oncologists in patient care and research. Research includes studies in BMT outcomes, 5FU cardiotoxicity and breast cancer treatment cardiotoxicity. He is associate editor for Cardiooncology, an editorial consultant for JACC Cardiooncology, and is a member of the IC-OS Science and Research Committee. He has multiple publications and presentations in the field.